Published in Women's Health Weekly, December 2nd, 2004
"Femara truly provides hope to women who have survived early breast cancer by offering them an improved chance of remaining cancer-free," said Diane Young, MD, vice president, global head, clinical development, Novartis oncology. "This priority review approval marks the first time that the nearly 100,000 women in the United States who complete tamoxifen therapy each year will have a medical option to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly